Last reviewed 2026-05-23 · How we verify

23ME-00610

23andMe, Inc. · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

23ME-00610 is a Small molecule drug developed by 23andMe, Inc.. It is currently in Phase 1 development.

23ME-00610 is being studied in a Phase 1/2a clinical trial for the treatment of advanced solid malignancies, including solid tumor, clear cell renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma. The study is a multicenter, open-label, dose-escalation and expansion study of intravenously administered 23ME-00610.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	23ME-00610
Sponsor	23andMe, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

23ME-00610 CI brief — competitive landscape report
23ME-00610 updates RSS · CI watch RSS
23andMe, Inc. portfolio CI

Frequently asked questions about 23ME-00610

What is 23ME-00610?

23ME-00610 is a Small molecule drug developed by 23andMe, Inc..

Who makes 23ME-00610?

23ME-00610 is developed by 23andMe, Inc. (see full 23andMe, Inc. pipeline at /company/23andme-inc).

What development phase is 23ME-00610 in?

23ME-00610 is in Phase 1.

Manufacturer: 23andMe, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing